Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: A bioinformatics study

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 2, 2015, Pages 2317-2325

  Lv, Jinli ^a,b   Zhu, Bo ^a   Zhang, Liang ^a   Xie, Qichao ^a   Zhuo, Wenlei ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b The 153 Central Hospital of Chinese PLA   (China)

Author keywords

Differentially expressed genes; Dysfunctional pathway; Function enrichment analysis; Hepatocellular carcinoma; Sorafenib resistance

Indexed keywords

ANTINEOPLASTIC AGENT; BRETYLIUM TOSYLATE; CALCIUM ION; CARISOPRODOL; CHLORAMBUCIL; CYTOCHROME P450; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN; LOMUSTINE; POLYSACCHARIDE; PREGNENOLONE; SORAFENIB; XENOBIOTIC AGENT;

ARACHIDONIC ACID METABOLISM; ARTICLE; BIOINFORMATICS; CELL ADHESION; DOWN REGULATION; DRUG DETERMINATION; DRUG METABOLISM; DRUG SCREENING; EXTRACELLULAR MATRIX; FOCAL ADHESION; GENE EXPRESSION; GENE ONTOLOGY; HEART RIGHT VENTRICLE DYSPLASIA; HEMOSTASIS; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; LIPOPROTEIN BLOOD LEVEL; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; PROTEIN LIPID INTERACTION; STEROID METABOLISM; UPREGULATION;

EID: 84926298845     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. [1] Makarova AS and Lazarevich NL. Deregulation of signaling pathways involved in sorafenib resistance of hepatocellular carcinoma. Klin Lab Diagn 2013; 66-68, 34-67.
2. [2] Page AJ, Cosgrove DC, Philosophe B and Pawlik TM. Hepatocellular carcinoma: diagnosis, ma-nagement, and prognosis. Surg Oncol Clin N Am 2014; 23: 289-311.
3. [3] Chen S, Wang Y, Ruan W, Wang X and Pan C. Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracel-lular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activity. Oncol Lett 2014; 8: 2333-2339.
4. [4] Chen W, Wu J, Shi H, Wang Z, Zhang G, Cao Y, Jiang C and Ding Y. Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways. Biomed Res Int 2014; 2014: 764981.
5. [5] Fernando J, Malfettone A, Cepeda EB, Vilar-rasa-Blasi R, Bertran E, Raimondi G, Fabra A, Alvarez-Barrientos A, Fernandez-Salguero P, Fernandez-Rodriguez CM, Giannelli G, Sancho P and Fabregat I. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer 2015; 136: E161-72.
6. [6] Li GM, Wang YG, Pan Q, Wang J, Fan JG and Sun C. RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells. Int J Clin Exp Pathol 2014; 7: 1085-1092.
7. [7] Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H, Jiang H and Sun X. Upregulation of HIF-2alpha induced by so-rafenib contributes to the resistance by activating the TGF-alpha/EGFR pathway in hepatocellular carcinoma cells. Cell Signal 2014; 26: 1030-1039.
8. [8] Fischer TD, Wang JH, Vlada A, Kim JS and Be-hrns KE. Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib. World J Hepatol 2014; 6: 752-758.
9. [9] Xia H, Ooi LL and Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepa-tology 2013; 58: 629-641.
10. [10] Hashimoto N, Tsunedomi R, Yoshimura K, Watanabe Y, Hazama S and Oka M. Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer 2014; 14: 722.
11. [11] Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S and Sun X. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Cancer Lett 2014; 355: 96-105.
12. [12] Zhang W, Liu S, Liu K, Ji B, Wang Y and Liu Y. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo. Oncol Rep 2014; 32: 1913-1922.
13. [13] Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu B, Pan S, Dong X, Tan G, Wei Z, Qiao H, Jiang H and Sun X. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther 2014; 13: 1589-1598.
14. [14] van Zijl F, Mall S, Machat G, Pirker C, Zeillinger R, Weinhaeusel A, Bilban M, Berger W and Mikulits W. A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol Cancer Ther 2011; 10: 850-860.
15. [15] Huang P, Cao K and Zhao H. Screening of critical genes in lung adenocarcinoma via network analysis of gene expression profile. Pathol Oncol Res 2014; 20: 853-858.
16. [16] Isozaki Y, Hoshino I, Akutsu Y, Hanari N, Mori M, Nishimori T, Murakami K, Akanuma N, Toyozumi T, Takahashi M, Suito H, Takeshita N, Maruyama T, Suzuki A, Nakayama T and Mat-subara H. Screening of Alternative Drugs to the Tumor Suppressor miR-375 in Esophageal Squamous Cell Carcinoma Using the Conne-ctivity Map. Oncology 2014; 87: 351-363.
17. [17] McCleland ML, Adler AS, Deming L, Cosino E, Lee L, Blackwood EM, Solon M, Tao J, Li L, Sh-ames D, Jackson E, Forrest WF and Firestein R. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clin Cancer Res 2013; 19: 773-784.
18. [18] McCleland ML, Adler AS, Shang Y, Hunsaker T, Truong T, Peterson D, Torres E, Li L, Haley B, Stephan JP, Belvin M, Hatzivassiliou G, Bla-ckwood EM, Corson L, Evangelista M, Zha J and Firestein R. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res 2012; 72: 5812-5823.
19. [19] Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H and Lu P. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One 2012; 7: e46670.
20. [20] Liu Y and Liu BA. Enhanced proliferation, invasion, and epithelial-mesenchymal transition of nicotine-promoted gastric cancer by periostin. World J Gastroenterol 2011; 17: 2674-2680.
21. [21] Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher HM, Harada T, Zhu M, Kalthoff H, Crnogorac-Jurcevic T and Lemoine NR. Peri-ostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene 2007; 26: 2082-2094.
22. [22] Januchowski R, Zawierucha P, Rucinski M and Zabel M. Microarray-based detection and expression analysis of extracellular matrix proteins in drugresistant ovarian cancer cell lines. Oncol Rep 2014; 32: 1981-1990.
23. [23] Zi FM, He JS, Li Y, Wu C, Wu WJ, Yang Y, Wang LJ, He DH, Yang L, Zhao Y, Zheng GF, Han XY, Huang H, Yi Q and Cai Z. Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through beta-catenin signaling pathway. Cancer Biol Ther 2014; 15: 1413-1422.
24. [24] Joyner DE, Trang SH, Aboulafia AJ, Damron TA and Randall RL. FAP-associated desmoid invasiveness correlates with in vitro resistance to doxorubicin. Fam Cancer 2009; 8: 569-580.
25. [25] Nishimoto SK and Nishimoto M. Matrix gla protein binds to fibronectin and enhances cell attachment and spreading on fibronectin. Int J Cell Biol 2014; 2014: 807013.
26. [26] Januchowski R, Zawierucha P, Rucinski M, Nowicki M and Zabel M. Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed Res Int 2014; 2014: 365867.
27. [27] Feng MX, Ma MZ, Fu Y, Li J, Wang T, Xue F, Zhang JJ, Qin WX, Gu JR, Zhang ZG and Xia Q. Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation. Mol Cancer 2014; 13: 226.
28. [28] Wei JS, Johansson P, Chen L, Song YK, Tolman C, Li S, Hurd L, Patidar R, Wen X, Badgett TC, Cheuk AT, Marshall JC, Steeg PS, Vaque Diez JP, Yu Y, Gutkind JS and Khan J. Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma. PLoS One 2013; 8: e77731.
29. [29] Lai KK, Shang S, Lohia N, Booth GC, Masse DJ, Fausto N, Campbell JS and Beretta L. Ex-tracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet 2011; 7: e1002147.
30. [30] Borriello L and DeClerck YA. Tumor microenvironment and therapeutic resistance process. Med Sci (Paris) 2014; 30: 445-451.
31. [31] Nguyen TV, Sleiman M, Moriarty T, Herrick WG and Peyton SR. Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening. Biomaterials 2014; 35: 5749-5759.
32. [32] Eke I and Cordes N. Focal adhesion signaling and therapy resistance in cancer. Semin Cancer Biol 2014; 31C: 65-75.
33. [33] Wang YJ, Zhang YK, Kathawala RJ and Chen ZS. Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Tran-sporters in Anticancer Drug Resistance. Can-cers (Basel) 2014; 6: 1925-1952.
34. [34] Truman JP, Garcia-Barros M, Obeid LM and Hannun YA. Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim Biophys Acta 2014; 1841: 1174-1188.
35. [35] Ramsay EE and Dilda PJ. Glutathione S-con-jugates as prodrugs to target drug-resistant tumors. Front Pharmacol 2014; 5: 181.
36. [36] Kesselring R, Thiel A, Pries R, Fichtner-Feigl S, Brunner S, Seidel P, Bruchhage KL and Wol-lenberg B. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack. Eur J Cancer 2014; 50: 2152-2161.
37. [37] Goyal J and Antonarakis ES. Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol 2013; 2013: 1-14.
38. [38] van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Ber-nsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T and Hoang-Xuan K. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31: 344-350.
39. [39] Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE, Kennedy DB, Pettitt AR, Nathwani A, Varghese A, Cohen D, Rawstron A, Oertel S and Pocock CF. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol 2014; 32: 1236-1241.
40. [40] Brain KL and Cunnane TC. Bretylium abolishes neurotransmitter release without necessarily abolishing the nerve terminal action potential in sympathetic terminals. Br J Pharmacol 2008; 153: 831-839.
41. [41] Spence MM, Shin PJ, Lee EA and Gibbs NE. Risk of injury associated with skeletal muscle relaxant use in older adults. Ann Pharmacother 2013; 47: 993-998.